The explosion of osteoporosis-related diagnostic
and therapeutic options in the past 6 to 10 years has created its own
challenges. Guidelines have recently been published concerning who
should be tested1 but, in a sense, that issue is moot. Bone
mass measurement technology is proliferating rapidly, and physicians
increasingly are confronted with ostensibly healthy individuals who
bring them a printout showing that they have low bone mass. Should the
physician recommend one of the growing array of bisphosphonates,
selective estrogen receptor modulators, hormone replacement therapy
regimens, or dietary supplements? Normally, the clinician treats the
patient, not a test, but when it comes to prevention, the test result
may be all the physician has to go on.
Heaney RP. Bone Mass, Bone Fragility, and the Decision to Treat. JAMA. 1998;280(24):2119–2120. doi:10.1001/jama.280.24.2119
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: